Cargando…
NADPH Selective Depletion Nanomedicine‐Mediated Radio‐Immunometabolism Regulation for Strengthening Anti‐PDL1 Therapy against TNBC
Anti‐PD(L)1 immunotherapy recently arises as an effective treatment against triple‐negative breast cancer (TNBC) but is only applicable to a small portion of TNBC patients due to the low PD‐L1 expression and the immunosuppressive tumor microenvironment (TME). To address these challenges, a multifunc...
Autores principales: | Wang, Ying, Gao, Di, Jin, Lin, Ren, Xuechun, Ouyang, Yanan, Zhou, Ying, He, Xinyu, Jia, Liangliang, Tian, Zhongmin, Wu, Dingcai, Yang, Zhe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875612/ https://www.ncbi.nlm.nih.gov/pubmed/36403210 http://dx.doi.org/10.1002/advs.202203788 |
Ejemplares similares
-
Research Progress of Conjugated Nanomedicine for Cancer Treatment
por: Zhao, Bin, et al.
Publicado: (2022) -
PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC)
por: Ghosh, Joydeep, et al.
Publicado: (2021) -
TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy
por: Singh, Desh Deepak, et al.
Publicado: (2021) -
[(89)Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models
por: Massicano, Adriana V. F., et al.
Publicado: (2023) -
Multifunctional Cargo-Free Nanomedicine for Cancer Therapy
por: Wang, Ying, et al.
Publicado: (2018)